



## GENERAL CONFORMITY CERTIFICATE

Pursuant to 15 U.S.C. § 2063(a), Gilead Sciences, Inc. certifies that based on a reasonable testing program, the product referenced in this certificate complies with applicable regulations, rules, bans, and/or standards that are enforced by the Consumer Product Safety Commission.

EFFECTIVE

This is an electronically controlled document. User is responsible for verifying and using the current effective version.

<b>Product:</b>	Harvoni® (Ledipasvir and Sofosbuvir) 33.7 mg/ 150 mg Oral Pellets, NDC 61958-1805-1
<b>The regulation(s), rule(s), ban(s), and/or standard(s) to which this product is being certified:</b>	CPSC 16 CFR 1700.20
<b>Manufacturer or importer certifying compliance:</b>	Gilead Sciences, Inc. 333 Lakeside Drive Foster City, CA 94404 USA Phone: 1-800-GILEAD-5
<b>Individual maintaining test records upon which this certification is based:</b>	Director of Global Operations Quality Assurance Gilead Sciences, Inc. 333 Lakeside Drive Foster City, CA 94404 USA Phone: 1-800-GILEAD-5 Email address: globalqa@gilead.com
<b>Date and place where this product was manufactured:</b>	Gilead products are coded with a unique lot number. The lot number can be used to identify the date and place of packaging by calling 1-800-GILEAD-5, prompt number 8.
<b>Date and place where this product was tested for compliance with the regulation(s), rule(s), ban(s) and/or standard(s) cited above and test report(s) on which certification is based:</b>	448 East Winchester Street, Suite 140 Murray, Utah 84107  Test Report # C200-1126 dated February 23, 2019  The specific test report applicable to this product depends on the configuration used.
<b>Third party laboratory that conducted testing upon which this certification is based:</b>	Child Related Research, Inc. 448 East Winchester Street, Suite 140 Murray, Utah 84107 Phone: (801) 904-3893

Effective Date: 03-Mar-2020